ClinicalTrials.gg
RecruitingNCT06761651Updated Jan 16, 2025

A Study of TAVO412 in Patients with Cancer (TAVO412)

A Phase 1 interventional study of TAVO412 in Cancer, sponsored by Tavotek Biotherapeutics. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by Tavotek Biotherapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Dec 2023, registered Dec 2024).
  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

TAVO412 Phase 1 is an open-label, non-randomized, 2-part Phase I study to examine the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of TAVO412. Part 1 will utilize a standard 3 + 3 design to determine the MTD/RP2D of TAVO412 in subjects with advanced or metastatic solid tumors who progressed on prior approved standard of care therapy. Part 2 will further evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and pharmacologic activity of TAVO412 in a new set of subjects with advanced or metastatic gastric cancer, non-small cell lung cancer (NSCLC), or subjects of other solid tumor types with best clinical responses (e.g., CR > PR > SD) from Part 1 that progressed on prior approved standard of care therapy.

Read the detailed description

This is an open-label, non-randomized, Phase I study to determine the safety and tolerability, define the MTD/RP2D, and assess the preliminary efficacy of TAVO412 in subjects with advanced or metastatic solid tumors who progressed on prior approved standard of care therapy. Subjects will receive TAVO412 at the tested dose intravenously on Day 1 and 15 in Cycle 1 and will continue this bi-weekly treatment schedule for all future cycles.

The study will be conducted in 2 parts:

Part 1 - Dose Escalation will determine the MTD and/or RP2D of TAVO412, which includes defining the optimal dose administration schedule.

Part 2 - Cohort Expansion will evaluate the recommended dose and administration schedule (MTD/RP2D) determined in Part 1 in a new set of subjects with advanced or metastatic gastric cancer, non-small cell lung cancer (NSCLC), or subjects of other solid tumor types with best clinical responses (e.g., CR > PR > SD) from Part 1 that progressed on prior approved standard of care therapy.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • TAVO412
03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Tavotek Biotherapeutics is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Male/female 18 years of age or older at the time of screening. 2. Voluntarily signed , understand the study and are willing to follow and have the ability to complete all trial procedures.

    3. Subjects with histologically or cytologically confirmed locally advanced unresectable or solid tumors that have failed standard therapy or have no standard therapy. There is no limit to the number of treatments that can be used in a previous regimen.

    4. performance status 0 or 1. 5. Expected survival ≥ 3 months. 6. Participants enrolled in Phase 2 must have at least one measurable ( v1.1 criteria) lesion, and participants enrolled in Phase 1 may also be enrolled if only non-measurable (RECIST v1.1 criteria) lesions are present. Neoplastic lesions located in the field of prior radiation therapy or treated with other local therapies are not considered measurable unless disease progression has been demonstrated.

    7. Phase 1: Subjects with advanced or metastatic solid tumors who have failed standard therapy or have no standard treatment.

    8. Phase 2: A new cohort of subjects with advanced or metastatic solid tumors who have failed or had no standard therapy and are of high prevalence in China, such as non-small cell lung cancer, gastric cancer, and liver cancer, or other solid tumor types with the best clinical response observed from Phase 1 (e.g., CR > PR > SD).

    1. For subjects with non-small cell lung cancer: histologically or cytologically confirmed non-small cell lung cancer with mutations or gene amplification in EGFR, MET, or VEGF genes, EGFR or cMET overexpression (refer to IHC≥2+ in the Central Laboratory Immunohistochemistry Antibody Interpretation Criteria, ≥ intermediate staining).
    2. For subjects with gastric cancer: histopathologically confirmed gastric cancer or gastroesophageal junction cancer (including lower esophageal adenocarcinoma) with mutations or gene amplifications in EGFR, MET, or VEGF genes, EGFR or cMET overexpression (IHC≥2+ in reference central laboratory immunohistochemistry antibody interpretation criteria, ≥ moderate staining).
    3. For subjects with hepatocellular carcinoma: histologically or cytologically pathologically confirmed primary hepatocellular carcinoma with mutations or gene amplification in EGFR, MET or VEGF, overexpression of EGFR or cMET (IHC≥2+ in reference central laboratory immunohistochemistry antibody interpretation standards, ≥ moderate staining).

Note: The tumor test report performed by the subject for other purposes (i.e., not a protocol-defined procedure) within 1 year prior to signing the consent form can be used as the basis for pre-treatment biopsy evaluation, and if metastases or recurrences of other tumors have occurred within 1 year, they are excluded.

9. Stage 2: Willing to undergo pre-treatment and end-of-treatment (if appropriate) tumor biopsy (rough needle aspiration or excision) of a tumor tissue sample for biomarker immunohistochemistry and genetic testing.

Note: Tumor biopsy archival tissue samples performed by subjects for other purposes (i.e., not protocol-defined procedures) within 1 year prior to signing the consent form may be used as pre-treatment tumor biopsy tissue samples, excluded if metastases or recurrences of other tumors have occurred within 1 year.

Note: Subjects are required to provide 4-6 blank sections with a layer thickness of 3-5 μm and 10-12 blank sections with a layer thickness of 8-10 μm, or preferably 1 tissue block for EGFR and cMET immunohistochemistry and polygenic mutation/amplification detection. If the amount of tumor tissue obtained is limited, it is important to prioritize the need for EGFR and cMET immunohistochemistry detection (at least 4 blank sections with a layer thickness of 3-5 μm), followed by tumor tissue polygenic detection (10-12 blank sections with a layer thickness of 8-10 μm), and finally FISH detection for EGFR and MET gene amplification of tumor tissue (4-6 blank sections with a thickness of 3-5 μm).

Note: Pre-treatment tumor tissue sections are not mandatory for subjects in Phase 2 if the tumor biopsy test report for other purposes (i.e., not a protocol-defined procedure) within 1 year prior to signing the consent form contains EGFR or cMET immunohistochemistry results. At the end of treatment, it is not suitable for/unwilling to provide tissue samples or other reasons that preclude tumor biopsy, and tumor biopsy is not mandatory.

Note: Tumor tissue samples are optional before and at the end of treatment in Phase 1, and best efforts should be made to obtain tumor tissue if possible. Test results are collected if the subject has had a tumor biopsy for other purposes (i.e., not a protocol-defined procedure) within 1 year prior to signing the consent form, and the test results contain EGFR, cMET, or VEGF.

10. For Phase 1 and Phase 2, subjects agree to collect additional peripheral blood for circulating tumor cell DNA (ctDNA) analysis.

11. Female subjects of (defined as not undergoing hysterectomy and/or bilateral oophorectomy sterilization surgery and not , menopausal is defined as amenorrhea ≥ 12 months) must have a negative blood pregnancy test at screening.

  1. All female subjects of childbearing potential must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening until 60 days after the last dose of study drug is administered. Male partners of female subjects (other than men who have been sterilized) must agree to use condoms correctly and on a continuous basis for the duration of the study and for 60 days after receiving the last dose of study drug.
  2. All male subjects (except those who have been sterilized) must agree to take appropriate precautions to avoid pregnancy with their partner (with at least 99% certainty) from screening until 90 days after the last dose of study drug administration. The female partner of male subjects (if of childbearing potential or less than 12 months postmenopausal) must agree to use a highly effective method of for the duration of the study and within 90 days of receiving the last dose of study drug. In addition, sperm donation is not allowed during the study and for 90 days after receiving the last dose of study drug.
  3. At least 99% effective contraceptive methods (see Appendix A) should be communicated to subjects and their understanding confirmed.

    12. All of the following criteria need to be met during the screening period, and if the following screening laboratory tests were performed > 7 days prior to the start of treatment, they will need to be repeated within 7 days prior to the start of treatment.

a. ≥ 1.5 ×109/L, ≥ 100 ×109/L, ≥9 g/dL or ≥5.6 mmol/L, and no transfusion of blood products (including platelets or red blood cells) or use of colony-stimulating factors (including granulocyte colony-stimulating factor, Granulocyte macrophage colony-stimulating factor or recombinant erythropoietin) (the of long-acting colony-stimulating factor or erythropoietin is at the discretion of the investigator).

b. and ALT≤2.5×(ULN)(AST and ALT in subjects with primary or metastatic liver cancer≤5× ULN)。 c. Total ≤ 1.5 × ULN (3× ULN for subjects with Gilbert's syndrome ≤), if there is no ULN at the study institution, direct bilirubin must be \< 40% of total bilirubin.

d. ≥ 30 mL/min (estimated by the Cockcroft-Gault formula, [140-age]× weight (Kg)/serum creatinine (mg/dl) × 72, or [140-age]× body weight (Kg)/serum creatinine (μmol/L) × 0.818, calculated × 0.85 for women).

e. (INR) ≤ 1.5× ULN, activated partial thromboplastin time (APTT) ≤ 1.5×ULN (without anticoagulant); INR ≤2.5×ULN, APTT≤2.5×ULN (those using anticoagulants).

13. (HIV)/ (HBV)/ (HCV) subjects will be allowed to participate in the study if the following criteria are met:

  1. HIV-infected subjects: CD4+ T cell (CD4+) count must be ≥ 350 cells/μL; Subjects with HIV infection-related tumors (e.g., Kaposi's sarcoma and invasive cervical cancer) were allowed to enroll; To ensure that subjects can tolerate effective antiretroviral therapy and that toxicity is not confused with study drug toxicity, subjects should receive at least four weeks of established antiretroviral therapy prior to enrollment and have an HIV viral load of less than 400 copies/mL and require replacement of specific ART drugs that may have overlapping toxicity or interaction with the study drug, and exclusion if no replaceable drug is available.
  2. Subjects who have no history of hepatitis B infection but have been vaccinated against hepatitis B and have tested positive for hepatitis B surface antibody by serology can participate in the study; HBV virus carriers or subjects with chronic active hepatitis B, whose HBV-DNA copy number is lower than the lower limit of normal in each center after anti-hepatitis B virus treatment, and whose liver function meets the above requirements can participate in the study.
  3. If the subject is positive for hepatitis C antibody, the HCV-RNA is lower than the lower limit of normal after drug treatment, and the subject is not at risk of hepatic insufficiency, he or she can participate in the study.

    Note: Viral replication and possible interactions and overlapping toxicities of antiviral therapy with the study drug should be closely monitored during the study participation in the above three categories of subjects

Exclusion criteria

Exclusion Criteria:

  • 1. Prior to the first dose of study drug, received an anticancer drug or drug at the following time intervals:

    • Chemotherapy, targeted small molecule therapy, or radiotherapy ≤ 14 days. Subject requires long-term use and develops radiation pneumonitis as a result of radiotherapy. A of 1 week after palliative radiotherapy for non-central nervous system (CNS) disease is allowed with the approval of the sponsor. Note: The investigator can judge the washout period at the discretion of the subject according to the subject's condition and the nature of the drug; TKI drugs have a short half-life, and the washout period is more than 5 half-lives.

Note: Bisphosphonates and denosumab are allowed concomitant medications. • ≤ immunotherapy or cell therapy prior to 28 days (i.e., chimeric antigen receptor T cell therapy; Other cell therapies must be discussed with the investigator to determine eligibility).

  • ≤ Monoclonal antibodies used for anticancer therapy prior to 28 days, with the exception of denosumab.
  • ≤ Chinese medicine used for anti-tumor before 14 days.
  • ≤ 7 days for therapy for any reason. Note: The use of inhaled or topical steroids or corticosteroids for imaging procedures is permitted.

Note: Physiologic corticosteroid replacement therapy may be approved after consultation with the investigator (systemic prednisone or equivalent corticosteroid doses of ≤10mg/day are allowed).

  • All other investigational drugs or devices are ≤ 28 days or 5 half-lives (whichever is longer) prior to the first dose. For investigational drugs with longer half-lives (e.g., > 5 days), investigator approval is required for enrollment prior to the fifth half-life.

2. Have not recovered from the toxic effects of prior therapy (including prior immunotherapy) and/or complications of surgical intervention to v5.0 score ≤ Grade 1.

Note: Subjects with stable chronic AEs (≤ Grade 2) that are not expected to resolve spontaneously (e.g., peripheral neuropathy and alopecia) are exceptions and may be enrolled after receiving investigator approval.

Note: Subjects with a history of clinically symptomatic ocular disease judged by the investigator to be severe or uncontrollable will be excluded, including but not limited to severe or uncontrollable keratitis, dry eye syndrome, conjunctivitis, blurred vision, visual impairment, uveitis, etc.

Note: Subjects with a history of prior therapy-related Grade 3 or higher AEs (excluding hematologic AEs) are excluded from the dose escalation portion of the study. The investigator can analyze the AE according to the time of occurrence and recovery.

3. Other malignant tumors at the same time, such as tumors that occurred and cured 5 years ago, do not affect enrollment: melanoma, skin cancer, carcinoma in situ or non-invasive tumors.

4. Previous cardiac disease within 6 months prior to the first study drug administration, including:

  • i. myocardial infarction, ii. Unstable angina, iii. Cerebrovascular accident, iv. Other acute uncontrollable cardiac disease;
  • History of clinically significant ventricular arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes);
  • (NYHA) Class III or IV congestive heart failure;
  • ≥470ms (Female) or≥450ms (Male) Or congenital long QT syndrome history or family history(Naring A,2012);
  • Arrhythmias requiring anti-arrhythmic drug therapy (subjects with atrial fibrillation with controlled heart rate > 1 month prior to the first dose of trial drug are eligible for enrollment); 5. Subjects who require local treatment or repeated drainage, and who are judged by the investigator to have poorly controlled effusions in body cavities (pleural effusion, ascites, pericardial effusion, etc.).

    6. Patients with recent gastrointestinal bleeding (defined as a history of hematemesis, visible hematochezia, or melena within the past 3 months (including hematochezia or melena due to hemorrhoids) without evidence of recovery confirmed by endoscopy or colonoscopy).

    7. Those with evidence of gastric bleeding or gastric perforation who will be excluded from participation at the discretion of the investigator.

    8. Those with pyloric obstruction or persistent recurrent vomiting (defined as vomiting ≥ 3 times in 24 hours) or those with acute intestinal obstruction are intubated.

    9. Those with a previous history of ulcerative colitis or Crohn's disease. 10. Those who have had active colitis, including infectious colitis, radiation colitis, and ischemic colitis, within 4 weeks prior to screening.

    11. Received a within 30 days of the start of the study drug program.

Note: Types of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/shingles, yellow fever, rabies, BCG, and typhoid vaccines. Seasonal influenza vaccines for injection are generally inactivated vaccines and are allowed; COVID-19 booster vaccine ≥ 4 weeks after the end of the study is allowed; However, intranasal influenza vaccine is a live-attenuated vaccine and is not allowed.

12. Active disease requiring systemic therapy (i.e., use of immunomodulators, corticosteroids, or immunosuppressive medications).

Note: Subjects who have not required systemic therapy in the past 2 years should discuss their condition with the investigator to determine enrollment.

Note: Subjects with hyperthyroidism/hypothyroidism may participate. Note: Hormone replacement therapy and symptomatic therapy (e.g., levothyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are not considered a form of systemic therapy and are permitted.

13. Known active central nervous system (CNS) and/or carcinomatous meningitis.

Note: Subjects with previously treated may participate provided that they are stable (no evidence of radiographic progression for at least 28 days prior to the first dose of study drug, and any neurological symptoms have returned to normal values), no evidence of new or enlarging brain metastases or central nervous system edema, and no steroid therapy or antiepileptic therapy is required for at least 14 days prior to the first dose of study drug.

14. Evidence of active non-infectious pneumonitis or interstitial pneumonitis during the screening period. Subjects who have suffered from interstitial pneumonia in the past and have recovered after treatment can be enrolled in this study after evaluation by the investigator.

15. Known serious vascular embolic event requiring medical or surgical intervention (≥ grade 2).

16. Active infection requiring systemic treatment, including COVID-19. 17. Known allergic reaction to any component of the study drug or formulation. 18. Females who are pregnant or lactating, or who are expected to become pregnant from the start of the screening visit until 60 days after the last 1 dose of study drug; 19. Men who plan to impregnate their partner from the start of the screening visit until 90 days after the last dose of study drug.

20. Any condition that, in the judgment of the investigator, would interfere with full participation in the study, including the use of study drugs and participation in required study visits; poses a significant risk to the subject; or interfere with the interpretation of the study.

Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Part 1 Cohort1

    150mg bi-weekly IV infusion of TAVO412

    Drug: TAVO412

  • Other
    Part 1 Cohort2

    375mg bi-weekly IV infusion of TAVO412

    Drug: TAVO412

  • Other
    Part 1 Cohort3

    750mg bi-weekly IV infusion of TAVO412

    Drug: TAVO412

  • Other
    Part 1 Cohort4

    1125mg bi-weekly IV infusion of TAVO412

    Drug: TAVO412

  • Other
    Part 1 Cohort5

    1500mg bi-weekly IV infusion of TAVO412

    Drug: TAVO412

  • Other
    Part 2 Cohorts

    RP2D IV infusion of TAVO412

    Drug: TAVO412

  • Other
    Part 1 Cohort6

    1750mg bi-weekly IV infusion of TAVO412

    Drug: TAVO412

Interventions

  • DrugTAVO412

    Biologic

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of TAVO412 according to Adverse Events and Number of Participants With Dose Limiting Toxicity (DLT) using National Cancer Institute CTCAE v5.0

    According to the frequency, duration, and severity of Adverse Events (AEs). The Dose Limiting Toxicity (DLT) is based on drug related adverse events and includes unacceptable hematologic toxicity, non-hematologic toxicity of Grade 3 or higher, or elevations in hepatic enzymes suggestive of drug-induced liver injury. The Common Terminology Criteria for Adverse Events (CTCAE) v5.0 has a minimum value of Grade 1, or mild, and a maximum value of Grade 4, Life-threatening; pressor or ventilatory support indicated. All DLTs will be assessed by the investigator using National Cancer Institute CTCAE v5.0.

    Time frame: Approximately 12 months

Secondary outcomes

  1. Maximum Serum Concentration (Cmax) of TAVO412

    The Cmax is the maximum observed serum concentration of TAVO412.

    Time frame: Approximately 12 months

  2. Time to Reach Maximum Observed Serum Concentration (Tmax) of TAVO412

    The Tmax is defined as time to reach maximum observed serum concentration of TAVO412.

    Time frame: Approximately 12 months

  3. Minimum Serum Concentration (Cmin) of TAVO412

    The Cmin is the minimum observed serum concentration of TAVO412.

    Time frame: Approximately 12 months

  4. Area Under the Serum Concentration-Time Curve From 0-1 (AUC[t0-t1])

    The AUC(t0-t1) is the area under the serum TAVO412 concentration-time curve from time t0 to t1.

    Time frame: Approximately 12 months

  5. Overall Response Rate (ORR)

    Overall Response Rate (ORR)

    Time frame: Approximately 12 months

  6. Duration of Response (DOR)

    DOR is defined as the time from earliest date of disease response (CR or PR) until earliest date of disease progression.

    Time frame: Approximately 12 months

  7. Progression-Free Survival (PFS)

    PFS is defined as the time from date of first dose of study drug until the earliest date of disease progression.

    Time frame: Approximately 12 months

  8. Duration of Disease Control (CR, PR, and SD)

    Duration of disease control is defined as the sum of PFS followed by maintenance.

    Time frame: Approximately 12 months

07

Study locations

4 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Legal restriction

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jan 2026, 24 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 24 months is below that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2024
First posted
Jan 7, 2025
StartActual
Dec 20, 2023
Primary completionEst.
Jan 1, 2026
CompletionEst.
Oct 15, 2026
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06761651
Lead sponsor
Tavotek Biotherapeutics
Responsible party
Sponsor
First posted
Jan 7, 2025
Start date
Dec 20, 2023
Primary completion
Jan 1, 2026 (estimated)
Completion
Oct 15, 2026 (estimated)
Last update
Jan 16, 2025

Study contacts

Yanjiao Yu, Bachelor
Contact
yanjiao.yu@tavotek.com
+86-13844867995
Wei Zhang, Master
Contact
wei.zhang@tavotek.com
+8618917679969
Suxia Luo, Dr.
principal investigator · Henan Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion